Clinical and Basic Investigations Into Known and Suspected Congenital Disorders of Glycosylation

• ClinicalTrials.gov Identifier: NCT02089789
• Recruitment Status: Recruiting
• First Posted: March 18, 2014
• Last Update Posted: May 26, 2023
• Sponsor: National Human Genome Research Institute (NHGRI)
• Information provided by (Responsible Party): National Institutes of Health Clinical Center (CC) ( National Human Genome Research Institute (NHGRI) )

Study Description

Brief Summary:

Background:

- Proteins, fats, and other molecules are the body s building blocks. Many of these molecules must have sugars, or chains of sugars, attached to work properly. People with congenital disorders of glycosylation (CDGs) cannot attach these sugars or sugar chains properly. A child or adult with a CDG can have symptoms in different parts of the body, including brain, nerves, muscles, liver, and immune system. Researchers want to learn more about these diseases to understand better what is causing the problems.

Objective:

- To learn more about CDGs.

Eligibility:

- People age 1-80 with CDG or suspected to have a CDG.

Design:

• CDG participants will stay in the hospital 3-5 days. They will have:
• Medical history and physical exam. They will answer questions about their CDG.
• Blood taken several times. Their skin will be numbed, then a needle will take blood from an arm vein.
• Samples taken of their skin, urine, and maybe stool and spinal fluid.
• Photos taken of their whole body. They can wear underwear and cover their eyes.
• Brain MRI. They will lie on a table that slides in and out of a metal cylinder. The scanner makes loud knocking noises so they can wear earplugs.
• Abdomen ultrasound. Sound waves take images of the body from the outside.
• Hand/wrist X-rays for young patients. They may have a full-body X-ray.
• DEXA bone density scan. Participants will lie on a table under a scanner.
• Echocardiogram and electrocardiogram for heart activity. Pads are stuck on the skin and the electrical activity of the heart is recorded.
• Tests of hearing, thinking, motor skills, and speech.
• Children participants may have tests done under sedation if it will benefit them directly.
• CDG participants may have other procedures during their visit. They may have follow-up visits every year.

Condition or disease
Congenital Disorders of Glycosylation

Detailed Description:

Congenital disorders of glycosylation (CDGs) are a group of diseases characterized by an abnormal glycosylation of proteins, but that can also result from an abnormal synthesis of glycosaminoglycans, glycophospholipids or glycosylphosphatidylinositol or the abnormal synthesis or utilization of dolichols. CDGs were first described in 1980, but the initial description of mutations in a gene underlying CDGs did not occur until 1997. Since then, there has been a rapid discovery phase of new CDGs, with more than 80 different types, reflecting defined mutations in 80 different genes in glycobiologic pathways affecting about 1000 patients worldwide. The clinical manifestations of CDGs are quite variable both within and among different types, and physicians from every specialty will likely encounter patients affected by glycosylation defects. The diagnosis of CDGs should be suspected in cases with neurological signs and symptoms of unknown etiology, or in any patient with multisystemic disease even in the absence of neurological features. Other potential clinical presentations include tissuespecific disorders such as anemia or ichthyosis, when common disorders have been ruled out. Diagnostic screening for many of the disorders is performed by analyzing the glycosylation on serum transferrin, initially by isoelectric focusing, now by mass spectrometry, in specialized clinical diagnostic laboratories both in the United States and abroad. The pattern of transferring glycoforms allows the differentiation between defects of Nglycosylation assembly in the ER (type I) and defects of Nglycan trimming and elongation, occurring mainly in the Golgi apparatus (type II). Most recently, wholeexome sequencing has led to the elucidation of the underlying mutation in patients with unknown CDGs. Treatment is available for only three CDG subtypes. In this protocol, we propose to clinically evaluate up to 100 patients of all ethnicities with known or suspected CDGs, obtain cells, plasma, and urine for future studies, perform mutation analysis for known CDGcausing genes, and search for other genes responsible for CDGs. Routine admissions of 3-5 days will occur annually or as required by changes in clinical symptomatology.

Study Design

• Study Type: Observational
• Estimated Enrollment: 150 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: Clinical and Basic Investigations Into Known and Suspected Congenital Disorders of Glycosylation
• Actual Study Start Date: March 7, 2014
• Estimated Primary Completion Date: December 1, 2023
• Estimated Study Completion Date: December 1, 2023

Groups and Cohorts

Group/Cohort
CDG; Patients with a suspected CDG based on biochemical tests or a confirmed CDG based on enzymatic or molecular tests will be eligible to enroll in this protocol

Outcome Measures

Primary Outcome Measures :

1. To perform molecular analysis to determine the molecular defects in the known CDG genes, search for new CDG-causing genes, and collect samples to create a library of biologic specimens from subjects with these disorders for related research. [ Time Frame: Ongoing ]
   To perform molecular analysis to determine the molecular defects in the known CDG genes, search for new CDG-causing genes, and collect samples to create a library of biologic specimens from subjects with these disorders for related research.

Eligibility Criteria

• Ages Eligible for Study: 1 Year to 80 Years (Child, Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No
• Sampling Method: Non-Probability Sample

Study Population

Anyone with a congenital disorder of glycosylation

Criteria

• INCLUSION/EXCLUSION CRITERIA:

Patients of any gender and ethnicity age 180 years with a suspected CDG based on biochemical tests or a confirmed CDG based on enzymatic or molecular tests will be eligible to enroll in this protocol. Patients will also be excluded if they cannot travel to the NIH due to their medical condition. Infants under age one year or under 10 kg of body weight are excluded because care is more readily provided to older infants at the Clinical Center.

Contacts and Locations

Contacts

Contact: Lynne A Wolfe, C.R.N.P.; (301) 443-8577; lynne.wolfe@nih.gov

Locations

United States, Maryland

National Institutes of Health Clinical Center; Recruiting

Bethesda, Maryland, United States, 20892

Sponsors and Collaborators

National Human Genome Research Institute (NHGRI)

Investigators

• Principal Investigator: Lynne A Wolfe, C.R.N.P.; National Human Genome Research Institute (NHGRI)

More Information

Additional Information:

NIH Clinical Center Detailed Web Page 

• Responsible Party: National Human Genome Research Institute (NHGRI)
• ClinicalTrials.gov Identifier: NCT02089789
• Other Study ID Numbers: 140071; 14-HG-0071
• First Posted: March 18, 2014
• Last Update Posted: May 26, 2023
• Last Verified: December 14, 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Undecided
• Plan Description: .pending

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by National Institutes of Health Clinical Center (CC) ( National Human Genome Research Institute (NHGRI) ):

Thrombosis; Intellectual Disability; Hypotonia; Hypoglycemia; Hypothyroidism; Natural History

Additional relevant MeSH terms:

Congenital Disorders of Glycosylation; Carbohydrate Metabolism, Inborn Errors; Metabolism, Inborn Errors; Genetic Diseases, Inborn; Metabolic Diseases